Periodic Reporting for period 4 - RevMito (Deciphering and reversing the consequences of mitochondrial DNA damage)
Période du rapport: 2018-12-01 au 2020-03-31
The overall objective of this project is to understand the cellular outcomes of mitochondrial disease. Toward this goal, we use mammalian cells and also budding yeast, a model system that has been historically invaluable in understanding mitochondrial assembly and dysfunction. Our specific focus is the relationship between mitochondrial dysfunction and intracellular signaling, protein transit to mitochondria, and proteostasis. Furthermore, we take unbiased approaches that are designed to reveal new and unexpected genes that control the response to mitochondrial dysfunction.
During the course of this grant action, we were indeed able to better understand the links between sugar sensation, protein import to mitochondria, and the outcome of mitochondrial dysfunction. Moreover, we were able to identify an additional protein, a lysine methyltransferase, which seems to impinge upon the outcome of mitochondrial dysfunction. We helped to illuminate how mitochondrial contact sites promote the intracellular distribution of mitochondrial metabolites. Finally, we developed novel approaches toward prediction of which mtDNA variants are likely to cause disease, and our studies of mitochondrial evolution are likely to provide further insight into key aspects of mitochondrial disease.
Certainly, the work funded by the ERC has been impactful, resulting in nine peer-reviewed publications, one pre-print submitted for peer-review, one book chapter accepted for publication, and several other manuscripts nearing completion and submission. This work has also been disseminated in the context of over 30 conferences and seminars. Active work continues on the important topics considered with the support of this EU funding.